CCM Biosciences breaks out of stealth with $25M; Two biotechs merge, to focus on Parkinson’s

CCM Bio­sciences launched out of stealth Tues­day, tout­ing ten drug pro­grams and more than $25 mil­lion raised from Se­ries A1 and A2 rounds.

CCM has a part­ner­ship with PMC Group, which is han­dling chem­istry, man­u­fac­tur­ing and con­trols for the biotech’s pro­grams. CCM CEO and co-founder Raj Chakrabar­ti is al­so the pres­i­dent of PMC Group In­ter­na­tion­al, ac­cord­ing to a me­dia re­lease.

A com­pa­ny pre­sen­ta­tion this month de­tailed some of CCM Bio­sciences’ drug pro­grams, in­clud­ing tar­get­ing non­sense mu­ta­tions, EGFR and KRAS for cys­tic fi­bro­sis, drug-re­sis­tant non-small cell lung can­cer and pan­cre­at­ic can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.